Stay updated with breaking news from John Quisel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has granted fast track designation to the investigational, anti-TMPRSS6 monoclonal antibody, MWTX-003 (DISC-3405), for use in the treatment of patients with polycythemia vera, according to an announcement from Disc Medicine, Inc.1
The FDA has granted Fast Track designation to MWTX-003 (DISC-3405) for the treatment of patients with polycythemia vera.
By Denny Jacob Disc Medicine's MWTX-003, a treatment for patients with polycythemia vera, was granted fast track designation by the U.S. Food and Drug...
By Denny Jacob Disc Medicine's MWTX-003, a treatment for patients with polycythemia vera, was granted fast track designation by the U.S. Food and Drug Administration. Chief Executive John...
Disc Medicine, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic... | June 9, 2023